Vulvovaginal Candidiasis Treatment Market is likely to witness steady growth, anticipated to reach USD 1607 Million by 2033: FMI

The global vulvovaginal candidiasis treatment market is currently valued at USD 1035 million in 2023 and is anticipated to expand at a CAGR of 4.5%. Owing to the technological advances in healthcare sector the market is likely to propel to USD 1607 Million by 2033.

VVC prevalence has increased due to growing diabetes cases and repeated antibiotic usage among individuals. The market is expected to grow due to an increase in R&D initiatives for precise diagnosis.

The high growth rate can be attributed to the rising disease burden of VVC and increasing testing rates. Positive changes, such as healthcare benefits by the government, increased awareness among consumers, and willingness to avail medical treatments are also expected to drive the growth of the vulvovaginal candidiasis treatment market.

Gain Valuable Market Knowledge: Request a Sample Report! https://www.futuremarketinsights.com/report-sample#5245502d47422d3135383735

Rapid increase in the global disease burden, coupled with escalating demand for better treatment options and increasing number of hospital-acquired infections, is also propelling the demand for bacterial vulvovaginal candidiasis treatment.

Furthermore, expanding healthcare infrastructure in developing economies, availability of pharmaceutical drugs, and robust technological advancements in the biopharmaceutical industries are all contributing to significant opportunities for vulvovaginal candidiasis treatment over the forecasted period.

Key Takeaways from the Market Study

• As of 2023, the vulvovaginal candidiasis treatment market was valued at USD 1035 Million
• From 2023 to 2033, the industry is poised to grow at a 4.5% CAGR
• By 2033, vulvovaginal candidiasis treatment market is slated to reach a valuation of USD 1607 Million
• By route of administration, the oral segment accounted for the largest share of   43.2% and is expected to continue this trend over the forecast period.
• China is poised to yield a CAGR of 4.2% with respect to vulvovaginal candidiasis treatment in 2033

“Increasing prevalence of VVC cases and technological advancement in healthcare are expected to radically transform the vulvovaginal candidiasis treatment market in the coming years,” comments an analyst at FMI.

Competitive Landscape

Astellas Pharma Inc., Mycovia Pharmaceuticals, Inc., Basilea Pharmaceutica Ltd., Scynexis, Inc., Grupo Ferrer Internacional S.A., Pfizer, Inc.,Cadila Pharmaceuticals,Bayer AG., Bristol-Myers Squibb Company are some of the key companies in the vulvovaginal candidiasis treatment market.

These players are continuously adopting various strategies such as new product launches, facility expansions, mergers, collaborations, partnerships, and acquisitions to increase their revenue share and gain a competitive edge in the market. for instance,

• In October 2022 – Astellas Pharma Inc. and Pantherna Therapeutics GmbH announced that the companies have entered into a new technology evaluation agreement for research to generate mRNA-based regenerative medicine programs using direct reprogramming (transdifferentiation)*.
• In August 2022 – Mycovia Pharmaceuticals, Inc. announced that it will present VIVJOA (oteseconazole) capsules in patients with recurrent vulvovaginal candidiasis (RVVC) at the 2022 Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) Annual Meeting. VIVJOA is the first and only FDA-approved medication for RVVC indicated to reduce the incidence of RVVC in females with a history of RVVC who are NOT of reproductive potential
• In July 2022 – Mycovia Pharmaceuticals, Inc. announced U.S. availability of VIVJOA (oteseconazole) capsules, an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential.

Interest in Market Trends: Get Detailed Analysis and Insights with Our Comprehensive Report! https://www.futuremarketinsights.com/reports/vulvovaginal-candidiasis-treatment-market

Key Segments Covered in the Vulvovaginal Candidiasis Treatment Market Industry Survey

By Drug Class:

• Clotrimazole
• Nystatin
• Fluconazole
• Ketoconazole
• Terbinafine
• Terconazole
• Others

By Route of Administration:

• Oral
• Intravenous
• Topical

By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region:

• North America
• Latin America
• Europe Direct
• South Asia
• East Asia
• Oceania
• MEA

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube